Chris A. Rallis - 15 Apr 2024 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A Rallis
Issuer symbol
FENC
Transactions as of
15 Apr 2024
Net transactions value
+$1,155
Form type
4
Filing time
15 Apr 2024, 18:15:20 UTC
Previous filing
27 Mar 2024
Next filing
08 Jul 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Sale $8,360 -800 -1.8% $10.45 44,449 15 Apr 2024 Direct F1
transaction FENC Common Shares Options Exercise $14,515 +1,389 +3.1% $10.45 45,838 15 Apr 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise $5,000 -1,389 -0.76% $3.60* 181,594 15 Apr 2024 Options 1,389 $3.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold to satisfy tax obligation on option exercise.
F2 Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
F3 Represents options exercised pursuant to a 10b5-1 program adopted August 17, 2023.